Blueprint Medicines Corp

Blueprint Medicines — ASH 2019 Annual Meeting

31 slides from Blueprint Medicines's conference presentation, Dec 9, 2019

  1. Slide 1: Systemic Mastocytosis Program Update ASH 2019

    Slide 1: Systemic Mastocytosis Program Update ASH 2019

    ASH 2019 R.S. Living with systemic mastocytosis Systemic Mastocytosis Program Update ASH 2019 ANNUAL MEETING DECEMBER 8, 2019

  2. Slide 2: Forward-looking statements

    Slide 2: Forward-looking statements

    ASH 2019 2 Forward-looking statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,”

  3. Slide 3: Agenda

    Slide 3: Agenda

    ASH 2019 3 Agenda Welcome Jeff Albers Chief Executive Officer Initial PIONEER trial data for avapritinib in indolent SM Daniel DeAngelo, MD, PhD Director, Clinical and Translational Research, Adult Leukemia, Dana-Farber Cancer Institute Associate Professor of Medicine, Harvard Medical School SM deve

  4. Slide 4: Our core mission and foundational principles

    Slide 4: Our core mission and foundational principles

    ASH 2019 4 Our core mission and foundational principles Blueprint Medicines aims to deliver on the promise of precision medicine to improve and extend the lives of patients with cancer and rare diseases. HIGHLY SELECTIVE INHIBITORS ADAPTIVE ABILITY PATIENT SELECTION

  5. Slide 5: Blueprint Medicines pipeline

    Slide 5: Blueprint Medicines pipeline

    ASH 2019 5 DISCOVERY EARLY-STAGE DEVELOPMENT LATE-STAGE DEVELOPMENT REGULATORY SUBMISSION APPROVED ongoing or completed planned NDA 2L RET+ NSCLC1,2 1L RET+ NSCLC1,2 EGFR+ NSCLC (+osimertinib)1,2 NDA 2L MTC1,2 Other RET-altered solid tumors1,2 Pralsetinib, formerly BLU-667 (RET) NDA / MAA PDGFRA GIS

  6. Slide 6: Comprehensive systemic mastocytosis clinical trial program

    Slide 6: Comprehensive systemic mastocytosis clinical trial program

    ASH 2019 6 Comprehensive systemic mastocytosis clinical trial program Advanced SM Phase 1 dose-escalation trial with open-label expansion Advanced SM Phase 2 single-arm trial Indolent SM Phase 2 randomized, double-blind, placebo-controlled trial

  7. Slide 7: Systemic mastocytosis represents a significant opportunity

    Slide 7: Systemic mastocytosis represents a significant opportunity

    ASH 2019 MOST ADULTS WITH CUTANEOUS SYMPTOMS WILL SHOW SYSTEMIC DISEASE WHEN FULLY INVESTIGATED 7 Systemic mastocytosis represents a significant opportunity Major markets include US, EU5 (France, Germany, Italy, Spain and the United Kingdom) and Japan. 1. Cohen S et al Br J Haematol (2014) 166(4):52

  8. Slide 8: PIONEER: Phase 2 Study of Avapritinib in Indolent or Smoldering SM

    Slide 8: PIONEER: Phase 2 Study of Avapritinib in Indolent or Smoldering SM

    PIONEER: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy American Society of Hematology Annual Meeting Orlando, FL, USA, December 8, 2019 Cem Akin, V

  9. Slide 9: Disclosures

    Slide 9: Disclosures

    Disclosures Dr. DeAngelo is an investigator on Blueprint Medicines’ ongoing EXPLORER and PATHFINDER trials in advanced SM and ongoing PIONEER trial in indolent SM Consultant: Blueprint Medicines, Celgene, Incyte, Jazz Pharmaceuticals, Novartis, Pfizer, Shire Research funding: AbbVie, Amgen, GlycoMim

  10. Slide 10: Systemic mastocytosis is one disease with a common genetic driver

    Slide 10: Systemic mastocytosis is one disease with a common genetic driver

    Systemic mastocytosis is one disease with a common genetic driver Advanced SM Aggressive SM SM with an associated hematologic neoplasm Mast cell leukemia Indolent SM Indolent SM Smoldering SM Life-threatening impact Requirement for high treatment intensity Debilitating symptoms Requirement for long-

  11. Slide 11: Avapritinib potently and selectively targets KIT D816V

    Slide 11: Avapritinib potently and selectively targets KIT D816V

    11 Avapritinib potently and selectively targets KIT D816V Biochemical binding by DiscoverRX at 3uM KIT D816V biochemical IC50 avapritinib* imatinib* masitinib# midostaurin* ripretinib# 0.27 nM 8150 nM >1000 nM 2.9 nM 2.6 nM Binding to other kinases (size is proportional to binding) avapritinib Gleev

  12. Slide 12: PIONEER clinical trial in patients with indolent SM

    Slide 12: PIONEER clinical trial in patients with indolent SM

    12 Phase 2 PIONEER clinical trial in patients with indolent SM Part 1: Dose Selection (fully enrolled) Part 2: Pivotal Efficacy (pending) Key Eligibility Criteria • Age ≥18 years, ECOG performance status 0–2 • Indolent SM or smoldering SM confirmed by central pathology review of bone marrow biopsy,

  13. Slide 13: Baseline patient demographics, disease characteristics and disposition

    Slide 13: Baseline patient demographics, disease characteristics and disposition

    13 Baseline patient demographics, disease characteristics and disposition All doses (N=39) Patient demographics Age (years), Median (range) 51 (21–75) Sex, n (%), Female 30 (77) ECOG PS, n (%), 0-1 2 31 (79) 8 (21) Disease characteristics Tryptase, µg/L, Mean (SD) Median (range) 84 (101) 45 (6–416)

  14. Slide 14: Baseline best supportive care medications recorded

    Slide 14: Baseline best supportive care medications recorded

    14 Baseline best supportive care medications recorded 42% 15% 18% 33% 36% 55% 67% 94% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Other supportive care Omatuzumab Corticosteroids Cromolyn sodium Proton pump inhibitors Leokotriene receptor antagonists H2 blockers H1 blockers Baseline BSC medications

  15. Slide 15: ISM-SAF a content-valid patient-reported outcomes tool for ISM

    Slide 15: ISM-SAF a content-valid patient-reported outcomes tool for ISM

    Symptom Domains Score Abdominal pain GI domain 0-10 scored daily Diarrhea Nausea Spots Skin domain Itching Flushing Brain Fog Headache Dizziness Bone pain Fatigue Total Symptom Score (TSS) 0-110 Design and Validation Concept elicitation and questionnaire construction Questionnaire evaluation Validat

  16. Slide 16: Baseline sign and symptom burden in patients enrolled in PIONEER

    Slide 16: Baseline sign and symptom burden in patients enrolled in PIONEER

    • Significant symptom burden in every patient enrolled • 84% of screened patients met minimum symptom burden eligibility requirement • Baseline median Total Symptom Score was 52 (range: 19–100) • Most severe symptoms in the 14 days prior to dosing were fatigue, brain fog, and flushing • Least severe

  17. Slide 17: Treatment-emergent adverse events (>10%), any grade

    Slide 17: Treatment-emergent adverse events (>10%), any grade

    17 Treatment-emergent adverse events (>10%), any grade avapritinib Preferred term, n (%) Placebo n=9 25 mg n=10 50 mg n=10 100 mg n=10 Total n=30 Number of subjects with ≥1 TEAE 8 (89) 9 (90) 8 (80) 8 (80) 25 (83) Nausea 2 (22) 0 6 (60) 3 (30) 9 (30) Headache 1 (11) 2 (20) 2 (20) 3 (30) 7 (23) Dizzi

  18. Slide 18: Percent change in serum tryptase from baseline by dose cohort

    Slide 18: Percent change in serum tryptase from baseline by dose cohort

    Percent change in serum tryptase from baseline by dose cohort 18 Avapritinib Timepoint Placebo 25 mg 50 mg 100 mg Cycle 1, Day 8 (first post-baseline assessment) 7.05% -37.72% -54.08% -56.16% Cycle 4, Day 1 (end of week 12) 0.39% -48.24% -66.67% -61.83% PIONEER data presented at ASH 2019 Annual Meet

  19. Slide 19: Summary of initial data from PIONEER trial Part 1

    Slide 19: Summary of initial data from PIONEER trial Part 1

    • At baseline, patients had moderate to severe symptoms despite best supportive care medications o The most severe patient-reported symptoms were fatigue, brain fog, flushing and cutaneous symptoms • Treatment with avapritinib at 25, 50 and 100 mg QD resulted in rapid decreases in serum tryptase • A

  20. Slide 20: Systemic mastocytosis development program update

    Slide 20: Systemic mastocytosis development program update

    ASH 2019 Systemic mastocytosis development program update Chief Medical Officer Andy Boral, MD, PhD

  21. Slide 21: Initial PIONEER data reinforce opportunity for avapritinib in indolent SM

    Slide 21: Initial PIONEER data reinforce opportunity for avapritinib in indolent SM

    ASH 2019 21 Initial PIONEER data reinforce opportunity for avapritinib in indolent SM Indolent SM population is larger than initially understood High symptom burden despite best available therapy Avapritinib is the only KIT D816V targeted therapy in clinical development Robust activity observed at a

  22. Slide 22: Next steps for PIONEER trial of avapritinib in indolent SM

    Slide 22: Next steps for PIONEER trial of avapritinib in indolent SM

    ASH 2019 22 Next steps for PIONEER trial of avapritinib in indolent SM Select RP2D PIONEER Registration-enabling Part 2 Complete enrollment of dose-finding Part 1 Report initial safety and serum tryptase data reported at ASH 2019 Plan to report additional Part 1 data, including patient-reported symp

  23. Slide 23: Plan to submit NDA for avapritinib for advanced SM in Q1 2020

    Slide 23: Plan to submit NDA for avapritinib for advanced SM in Q1 2020

    ASH 2019 23 Plan to submit NDA for avapritinib for advanced SM in Q1 2020 based on combined data from EXPLORER and PATHFINDER trials Advanced SM Phase 1 dose-escalation trial with open-label expansion Advanced SM Phase 2 single-arm trial ENROLLMENT TARGETS REACHED IN BOTH EXPLORER AND PATHFINDER TRI

  24. Slide 24: Top-line EXPLORER data: decline in mast cell burden in nearly all patients

    Slide 24: Top-line EXPLORER data: decline in mast cell burden in nearly all patients

    ASH 2019 Top-line EXPLORER data: decline in mast cell burden in nearly all patients Bone marrow mast cells KIT D816V mutant allele fraction Serum tryptase Spleen volume Maximum Percent Change from Baseline Maximum Percent Change from Baseline Maximum Percent Change from Baseline Maximum Percent Chan

  25. Slide 25: Top-line EXPLORER data: high rate and prolonged duration of response

    Slide 25: Top-line EXPLORER data: high rate and prolonged duration of response

    ASH 2019 • FDA breakthrough therapy designation3 • Robust activity across all disease subtypes • Median follow up of 21 months with ongoing treatment up to ~3.5 years1 Top-line EXPLORER data: high rate and prolonged duration of response 1. Top-line EXPLORER trial data reported on December 8, 2019. D

  26. Slide 26: BLU-263 is a next-generation KIT inhibitor

    Slide 26: BLU-263 is a next-generation KIT inhibitor

    ASH 2019 PLAN TO INITIATE PHASE 1 TRIAL IN HEALTHY VOLUNTEERS IN MID 2020 26 BLU-263 is a next-generation KIT inhibitor designed to enable chronic therapy in a broad population of patients with mast cell disorders POTENT Sub-nanomolar potency against KIT D816V CNS PROFILE Designed to not cross blood

  27. Slide 27: A comprehensive development program for mast cell disorders

    Slide 27: A comprehensive development program for mast cell disorders

    ASH 2019 27 A comprehensive development program designed to address a broad population of patients with mast cell disorders Program Research Early Development Late Development Regulatory Submission Advanced SM Indolent SM Mast cell disorders Avapritinib NDA Q1 2020 Avapritinib PIONEER Part 21 1H 202

  28. Slide 28: Q&A

    Slide 28: Q&A

    Q&A

  29. Slide 29: Closing remarks

    Slide 29: Closing remarks

    ASH 2019 Closing remarks Chief Executive Officer Jeff Albers

  30. Slide 30: Anticipated near-term milestones for SM, GIST and RET programs

    Slide 30: Anticipated near-term milestones for SM, GIST and RET programs

    ASH 2019 • February 14, 2020 PDUFA date for PDGFRA GIST NDA • Report top-line VOYAGER trial data in 3L GIST in Q2 2020 • Expect PDUFA date for 4L+ GIST NDA in Q2 2020 Anticipated near-term milestones for SM, GIST and RET programs Avapritinib Gastrointestinal stromal tumors • Initiate Phase 3 trial i

  31. Slide 31: ™

    Slide 31: ™

    ™

Source: SEC EDGAR · 8-K filed Dec 9, 2019

More decks from Blueprint Medicines Corp